- Home
- PHAT vs ATLC Comparison
PHAT vs ATLC Comparison
Compare PHAT & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- ATLC
- Stock Information
- Founded
- PHAT 2018
- ATLC 1996
- Country
- PHAT United States
- ATLC United States
- Employees
- PHAT N/A
- ATLC N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- PHAT Health Care
- ATLC Finance
- Exchange
- PHAT Nasdaq
- ATLC Nasdaq
- Market Cap
- PHAT 820.8M
- ATLC 900.3M
- IPO Year
- PHAT 2019
- ATLC 1999
- Fundamental
- Price
- PHAT $11.66
- ATLC $75.12
- Analyst Decision
- PHAT Strong Buy
- ATLC Buy
- Analyst Count
- PHAT 5
- ATLC 7
- Target Price
- PHAT $16.40
- ATLC $66.14
- AVG Volume (30 Days)
- PHAT 1.1M
- ATLC 37.9K
- Earning Date
- PHAT 11-06-2025
- ATLC 11-06-2025
- Dividend Yield
- PHAT N/A
- ATLC N/A
- EPS Growth
- PHAT N/A
- ATLC 35.13
- EPS
- PHAT N/A
- ATLC 5.69
- Revenue
- PHAT $114,039,000.00
- ATLC $457,158,000.00
- Revenue This Year
- PHAT $207.52
- ATLC $289.31
- Revenue Next Year
- PHAT $96.46
- ATLC $11.95
- P/E Ratio
- PHAT N/A
- ATLC $11.89
- Revenue Growth
- PHAT 1049.82
- ATLC 26.20
- 52 Week Low
- PHAT $2.21
- ATLC $30.00
- 52 Week High
- PHAT $19.71
- ATLC $69.94
- Technical
- Relative Strength Index (RSI)
- PHAT 54.88
- ATLC 81.22
- Support Level
- PHAT $11.89
- ATLC $66.55
- Resistance Level
- PHAT $13.00
- ATLC $69.61
- Average True Range (ATR)
- PHAT 0.71
- ATLC 2.04
- MACD
- PHAT -0.11
- ATLC 0.21
- Stochastic Oscillator
- PHAT 26.57
- ATLC 100.00
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.